Yanjiang Xing, Yangfeng Hou, Tianfei Fan, Ran Gao, Xiaohang Feng, Bolun Li, Junling Pang, Wenjun Guo, Ting Shu, Jinqiu Li, Jie Yang, Qilong Mao, Ya Luo, Xianmei Qi, Peiran Yang, Chaoyang Liang, Hongmei Zhao, Wenhui Chen, Jing Wang, Chen Wang
Pulmonary hypertension (PH) is a fatal disorder characterized by pulmonary vascular remodeling and obstruction. The phosphodiesterase 4 (PDE4) family hydrolyzes cyclic AMP (cAMP) and is comprised of four subtypes (PDE4A-D). Previous studies have shown the beneficial effects of pan-PDE4 inhibitors in rodent PH; however, this class of drugs is associated with side effects owing to the broad inhibition of all four PDE4 isozymes. Here, we demonstrate that PDE4B is the predominant PDE isozyme in lungs and that it was upregulated in rodent and human PH lung tissues...
April 2024: Acta Pharmaceutica Sinica. B